SYRE — Spyre Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
U.S. STOCKS ON THE MOVE-MYR Group, Spyre Therapeutics, AMD
Spyre Therapeutics slips on $350 mln share sale
Brief: Spyre Therapeutics Announces Pricing Of $350.0 Million Public Offering Of Common Stock
Brief: Spyre Therapeutics Announces Proposed Public Offering Of Its Common Stock
U.S. STOCKS ON THE MOVE-Pyxis Oncology, MongoDB, United Therapeutics
U.S. STOCKS ON THE MOVE-Synopsys, Cboe, GameStop
Spyre gains after Merck's drug succeeds in skin disease trial
Brief: Spyre Announces Potential Best-In-Class Spy003 (Anti-Il-23) Part A Induction Results From Skyline Trial, Completing Proof-Of-Concept For All Three Components Of Its Ibd Combinations
U.S. RESEARCH ROUNDUP-CrowdStrike, Nvidia, Macerich
U.S. STOCKS ON THE MOVE-Williams-Sonoma, Kraft Heinz, Evommune
U.S. STOCKS ON THE MOVE-Revolution Medicines, Abercrombie & Fitch, Williams-Sonoma
U.S. STOCKS ON THE MOVE-Meta, Kohl's, J.M. Smucker
U.S. STOCKS ON THE MOVE-Semtech, Donaldson, Meta
Spyre falls after arthritis drug misses development target
U.S. RESEARCH ROUNDUP- Intuit, MongoDB, Zscaler
Brief: Spyre Therapeutics Announces Topline Results From The Rheumatoid Arthritis Sub-Study Of The Skyway Phase 2 Trial Of Spy072
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics